Amyloidosis Stakeholder Partnerships for
Impact, Reach and Equity
About ASPIRE
ASPIRE’s mission is to collectively power inclusive and accessible solutions in partnership with the broader amyloidosis community to improve quality of life and health outcomes.
![]()
Established in 2021, the ASPIRE: Amyloidosis Industry Collaborative convenes leading companies in a pre-competitive space to address some of the most urgent issues faced by the amyloidosis community. Through partnership we are driven to shift the discourse and demonstrate what can be done when leaders work together on behalf of rare disease patients.
ASPIRE aims to accelerate progress in the areas of diagnosis, care, and address health disparities through collaborative project design and shared resources, arriving at solutions that address common challenges and unmet need.
Priority Initiatives

Coordinated Care Working Group

Diagnostic Pathways Working Group

Health Equity Working Group
Executive Steering Committee Members
Impact
Value of Artificial Intelligence for Enhancing Suspicion of Cardiac Amyloidosis Using Electrocardiography and Echocardiography: A Narrative Review
View the publication →
ASPIRE: Industry Collaborative, Member Companies
Contact
To learn more please contact Megan Glynn, Senior Program Manager for ASPIRE, at mglynn@arci.org.

